Lymphangiogenesis: A new player in cancer progression

被引：59
作者：
Nagahashi, Masayuki [1 ,2 ]
Ramachandran, Subramaniam [1 ,2 ]
Rashid, Omar M. [1 ,2 ]
Takabe, Kazuaki [1 ,2 ]
机构：
[1] Virginia Commonwealth Univ, Div Surg Oncol, Dept Surg, Massey Canc Ctr, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Div Surg Oncol, Dept Surg, Sch Med, Richmond, VA 23298 USA
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2010年 / 16卷 / 32期
关键词：
Colorectal neoplasms; Angiogenesis; Lymphangiogenesis; Lymphatic vessels; Lymphatic metastasis; Vascular endothelial growth factor; Monoclonal antibody D2-40; Therapy-related neoplasms; Biomarkers; GROWTH-FACTOR-C; LYMPH-NODE METASTASIS; HUMAN COLORECTAL-CANCER; VEGF-D EXPRESSION; ENDOTHELIAL-CELLS; MICROVESSEL DENSITY; TUMOR LYMPHANGIOGENESIS; PROGNOSTIC IMPLICATIONS; TARGETED THERAPY; INTRATUMORAL LYMPHANGIOGENESIS;
D O I：
10.3748/wjg.v16.i32.4003
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Lymph node metastasis is the hallmark of colon cancer progression, and is considered one of the most important prognostic factors. Recently, there has been growing evidence that tumor lymphangiogenesis (formation of new lymphatic vessels) plays an important role in this process. Here, we review the latest findings of the role of lymphangiogenesis in colorectal cancer progression, and discuss its clinical application as a biomarker and target for new therapy. Understanding the molecular pathways that regulate lymphangiogenesis is mandatory to pave the way for the development of new therapies for cancer. In the future, tailored treatments consisting of combinations of chemotherapy, other targeted therapies, and anti-lymphangiogenesis agents will hopefully improve patient outcomes. This progression to the clinic must be guided by new avenues of research, such as the identification of biomarkers that predict response to treatment. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码：4003 / 4012
页数：10
相关论文
共 116 条
[1]   Molecular mechanisms of lymphangiogenesis in health and disease [J].
Alitalo, K ;
Carmeliet, P .
CANCER CELL, 2002, 1 (03) :219-227
[2]  
ANELLI V, 2010, FASEB J
[3]  
Beasley NJP, 2002, CANCER RES, V62, P1315
[4]   Absence of the cell cycle inhibitor p27Kip1 protein predicts poor outcome in patients with stage I-III colorectal cancer [J].
Belluco, C ;
Esposito, G ;
Bertorelle, R ;
Del Mistro, A ;
Fassina, A ;
Vieceli, G ;
Chieco-Bianchi, L ;
Nitti, D ;
Lise, M .
ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (01) :19-25
[5]   High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer [J].
Bono, P ;
Wasenius, VM ;
Heikkilä, P ;
Lundin, J ;
Jackson, DG ;
Joensuu, H .
CLINICAL CANCER RESEARCH, 2004, 10 (21) :7144-7149
[6]   Lymphangiogenesis: in vitro and in vivo models [J].
Bruyere, Francoise ;
Noel, Agnes .
FASEB JOURNAL, 2010, 24 (01) :8-21
[7]   PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis [J].
Cao, RH ;
Björndahl, MA ;
Religa, P ;
Clasper, S ;
Garvin, S ;
Galter, D ;
Meister, B ;
Ikomi, F ;
Tritsaris, K ;
Dissing, S ;
Ohhashi, T ;
Jackson, DG ;
Cao, YH .
CANCER CELL, 2004, 6 (04) :333-345
[8]   Hepatocyte growth factor is a lymphanoiogenic factor with an indirect mechanism of action [J].
Cao, RH ;
Björndahl, MA ;
Gallego, MI ;
Chen, SH ;
Religa, P ;
Hansen, AJ ;
Cao, YH .
BLOOD, 2006, 107 (09) :3531-3536
[9]   Vascular endothelial growth factor C induces angiogenesis in vivo [J].
Cao, YH ;
Linden, P ;
Farnebo, J ;
Cao, RH ;
Eriksson, A ;
Kumar, V ;
Qi, JH ;
Claesson-Welsh, L ;
Alitalo, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14389-14394
[10]  
Cao YH, 2005, CELL CYCLE, V4, P228
12345678910